Open AccessThis article is
- freely available
HIV Genetic Diversity and Drug Resistance
Laboratório de Virologia Humana, Universidade Federal do Rio de Janeiro, CCS, Bloco A, sala A2-120, Cidade Universitária, Ilha do Fundão, 21949-570, Rio de Janeiro, RJ, Brazil
Programa de Genética, Instituto Nacional de Câncer, Rio de Janeiro, Brazil
* Author to whom correspondence should be addressed.
Received: 18 November 2009; in revised form: 11 December 2009 / Accepted: 1 February 2010 / Published: 2 February 2010
Abstract: Most of the current knowledge on antiretroviral (ARV) drug development and resistance is based on the study of subtype B of HIV-1, which only accounts for 10% of the worldwide HIV infections. Cumulative evidence has emerged that different HIV types, groups and subtypes harbor distinct biological properties, including the response and susceptibility to ARV. Recent laboratory and clinical data highlighting such disparities are summarized in this review. Variations in drug susceptibility, in the emergence and selection of specific drug resistance mutations, in viral replicative capacity and in the dynamics of resistance acquisition under ARV selective pressure are discussed. Clinical responses to ARV therapy and associated confounding factors are also analyzed in the context of infections by distinct HIV genetic variants.
Keywords: HIV-1; drug resistance; genetic diversity; subtypes; clinical response
Citations to this Article
Cite This Article
MDPI and ACS Style
Santos, A.F.; Soares, M.A. HIV Genetic Diversity and Drug Resistance. Viruses 2010, 2, 503-531.
Santos AF, Soares MA. HIV Genetic Diversity and Drug Resistance. Viruses. 2010; 2(2):503-531.
Santos, André F.; Soares, Marcelo A. 2010. "HIV Genetic Diversity and Drug Resistance." Viruses 2, no. 2: 503-531.